{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-25-000085","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.847665+00:00","generated_at":"2026-05-19T00:00:20.226755+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Compass Pathways positive Phase 3 COMP005 psilocybin trial meets primary endpoint for TRD","bullets":["COMP360 25 mg single dose showed MADRS reduction -3.6 vs placebo (p<0.001) at week 6.","DSMB chair: no new safety findings; no clinically meaningful imbalance in suicidality.","258 participants enrolled across 32 US sites; blinded extension to week 26, open-label to 52.","COMP006 (568 participants) 26-week data expected H2 2026; company plans FDA discussions.","First pivotal Phase 3 positive; supports regulatory path for COMP360 in treatment-resistant depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-25-000085","json":"https://secwatch.observer/filing/0001816590-25-000085.json","markdown":"https://secwatch.observer/filing/0001816590-25-000085.md","text":"https://secwatch.observer/filing/0001816590-25-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/0001816590-25-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659025000085/cmps-20250623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T00:00:20.226755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}